Natco Pharma Gets One Observation From USFDA For Kothur Formulation Facility

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has announced the completion of a Pre-Approval inspection from the United States Food and Drug Administration (USFDA) for its Formulation facility in Kothur Village, near Hyderabad, India, which was conducted from 2nd March to 6th March, 2020.

At the end of the inspection, the facility received a single observation related to equipment qualification of a co-mill used in the process that had operating speed slightly outside the qualification range. The company believes that this is a minor observation and can be addressed within a short period of time.

The company will provide due justification and corrective action plan within the next 15 working days to address this observation.

Shares of NATCO PHARMA LTD. was last trading in BSE at Rs.602 as compared to the previous close of Rs. 608.55. The total number of shares traded during the day was 5125 in over 739 trades.

The stock hit an intraday high of Rs. 605.25 and intraday low of 572.4. The net turnover during the day was Rs. 3030470.-Equity Bulls